Nevertheless, blocking XIAP function by transient overexpression of Smac achieved a promising enhanced efficacy in combination with TRAIL in prostate cancer cell lines [46], indicating that XIAP is the predominant target for TRAIL sensitivity. The gene discussed is TNFSF10; the disease is Familial prostate cancer.